stop at data collection, Delve operates the execution layer that keeps studies running: proactive patient outreach in 120+ languages, device troubleshooting, wear-time monitoring, signal quality control, and site burden reduction. The result is 92–98% ePRO completion rates and sustained wearable compliance across Phase II, Phase III, post-market, and long-duration follow-up studies. Delve serves sponsors and CROs across oncology, CNS, cardiovascular, rare disease, dermatology, respiratory, and metabolic disease — with experience across North America, Europe, Asia, and MENA. Headquartered in Minneapolis, Minnesota.